Want to land a Big Pharma deal? Be transparent, bring strong data and don't spam executives on LinkedIn. Dealmakers from GSK, Lilly, J&J, Bayer and Merck shared their advice at Fierce's London event. fiercebiotech.com/biotech/wh…
Biogen's tau-targeting Alzheimer's therapy was linked to a 38% slowing of clinical decline at 96 weeks, strengthening the case for late-stage development despite a mixed phase 2 readout. fiercebiotech.com/biotech/bi…
13
1,814
Pfizer is entering the in vivo CAR-T race with a deal worth up to $2.6 billion for three preclinical autoimmune programs from China’s Starna Therapeutics, including $330 million upfront. fiercebiotech.com/biotech/pf…
Marrow Therapeutics has launched with $173 million in funding to advance a preclinical therapy targeting sickle cell disease and beta thalassemia. fiercebiotech.com/biotech/ma…
Isomorphic Labs has pulled off another massive financing, raising $5 billion in a series C just six months after securing $2.1 billion for its AI drug development platform. fiercebiotech.com/biotech/is…
Another setback for Kyntra Bio. The former FibroGen has scrapped its phase 2 prostate cancer ADC program after failing to meet an efficacy threshold. fiercebiotech.com/biotech/ky…
Could 2027 be Europe's year to shine? At Fierce's London Life Sciences Week event, investors weighed the region's biotech funding challenges and opportunities. fiercebiotech.com/biotech/fi…
Regeneron's baloncibart met the primary endpoint in a phase 2 trial for POTS, a disorder with no FDA-approved treatments. The company now plans to launch a potentially pivotal study in 2027. fiercebiotech.com/biotech/re…
Sanofi-backed Windward Bio has hit its $225M IPO target to advance its respiratory pipeline, even as fellow biotech Rezera delays its own public offering, citing market conditions. fiercebiotech.com/biotech/sa…
Cellectis plans to cut up to 70% of its workforce through 2027 as the biotech shifts away from allogeneic CAR-T therapies to focus on in vivo gene editing. fiercebiotech.com/biotech/ce…
MetaVia's GLP-1/glucagon drug reduced liver fat and body weight in a phase 1 trial, but questions remain about its competitive edge. The biotech is now targeting a less crowded corner of the liver disease market. fiercebiotech.com/biotech/me…
2
8
3,834
Rezera, formerly known as NodThera, is targeting $181 million in IPO proceeds to advance its lead NLRP3 inhibitor into a phase 3 trial for peripheral artery disease next year. fiercebiotech.com/biotech/re…
Evommune is joining Novartis in the race to develop VAV1-targeting molecular glue degraders, striking a deal worth up to $1.1 billion with China's Hinova Pharmaceuticals. fiercebiotech.com/biotech/ev…
Just two months after launching a phase 1 trial, Sanofi is pulling the plug on a STAT6 degrader licensed from Nurix. The decision comes amid a broader pipeline shake-up under Sanofi's new CEO. fiercebiotech.com/biotech/sa…
Ultragenyx is cutting 20% of its workforce and shelving drug development programs as it looks to halve R&D spending and reach profitability in 2027. The overhaul follows a string of clinical setbacks. fiercebiotech.com/biotech/ul…
Boehringer Ingelheim is doubling down on Chinese biotech innovation, striking a deal worth up to $7.4 billion with Sino Biopharmaceutical for six preclinical cancer programs spanning ADCs and T-cell engagers. fiercebiotech.com/biotech/bo…
After $2.2 billion in impairment charges weighed on quarterly profits, Novo Nordisk is still looking to acquisitions to fill gaps in its pipeline. fiercebiotech.com/biotech/no… $NVO
FierceBiotech retweeted
Enhertu has transformed HER2 breast cancer treatment and set a high bar for the next generation of drugs. Now, the race is on to develop something even better, but finding a worthy successor is proving to be easier said than done. fiercebiotech.com/biotech/ad…
Our annual Biotech Graveyard returns to remember the drug developers that shut their doors this year and the science that may yet live on. fiercebiotech.com/biotech/20…
Zentalis is already preparing for a potential U.S. launch of its WEE1 inhibitor azenosertib after encouraging ovarian cancer data at ESMO. CEO Julie Eastland tells Fierce why the biotech sees a commercial opportunity. fiercebiotech.com/biotech/es… #ESMO26

